Industry news
Genetech/Roche acquires Jecure therapeutics and its preclinical portfolio of NLRP3 inhibitors a prospective treatment for NASH
Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases,announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure�s entire preclinical portfolio of NLRP3 inhibitors.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
